Coeptis Therapeutics closes SPAC deal with Bull Horn

1 November 2022

Having soared as much as 164% earlier in the day, shares of USA-based Coeptis Therapeutics (OTC PINK: COEP) closed down 45% at $6.50 on the Nasdaq, after it announced the completion of its business combination with Bull Horn Holdings (Nasdaq: BHSE), a special purpose acquisition company (SPAC).

The combined company has been renamed "Coeptis Therapeutics Holdings,” and its public shares and warrants are expected to commence trading on the Nasdaq Global Market under the ticker symbols "COEP" and "COEPW," respectively, October 31, 2022. The company will continue to focus primarily on the development of innovative cell therapy platforms for patients with cancer.

Under the terms of the combination, the former stockholders of Coeptis exchanged their shares of common stock for common stock of Bull Horn at a rate of 2.96851721 for 1. Following that, the company has around 19.5 million shares of common stock issued and outstanding, with the former stockholders of Coeptis now owning about 88% of the company, and the existing shareholders of Bull Horn about 12% of the company.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK